Ruxolitinib maker?

Ruxolitinib is most commonly sold under the brand name Jakafi.
The drug was originally developed and is now manufactured by Incyte Corporation (U.S. headquarters in Wilmington, Delaware). Incyte holds the commercial rights for Jakafi and oversees all manufacturing, quality control, and distribution.

Quick facts about the maker

Additional context

• Generic versions – In 2024, a generic form of ruxolitinib became available through the FDA’s generic pathway (e.g., by Sandoz, Teva, etc.). These generics are chemically identical but may be sold under different trade names or as “generic ruxolitinib.”
• Manufacturing – Incyte’s manufacturing sites are located in the United States and the United Kingdom, where they comply with Good Manufacturing Practice (GMP) standards.
• Research & development – Beyond Jakafi, Incyte continues to explore other indications for ruxolitinib and new JAK inhibitors.

If you’re looking for specifics such as batch numbers, distribution partners, or pricing, let me know—happy to dive deeper!